A target trial was emulated with two treatment strategies: continuation of dispensing into the first trimester or noncontinuation
The outcome of this study demonstrated that VC was just as effective as FC, and both treatment groups significantly improved all the measured skin parameters over that of placebo-control values
Since both formulations contain the same active ingredient, weight loss outcomes are similar when doses are equivalent and adherence is consistent
Additionally, AAV2/9-Sesn2 treatment enhanced Sestrin2 protein levels, phosphorylation of AMPK and eNOS, inhibited phosphorylation of mTOR, promoted Sigma-1 receptor expression, increased phosphorylation of IRE1, and elevated XBP1s levels
You should seek clinical advice if you experience persistent or severe abdominal pain, vomiting, signs of dehydration, or digestive discomfort that worsens over time